Molecular Pharmacology (USA), Ltd.

MLPHOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$111554

P/E Ratio—

52W High$0.0097

52W Low$0.0001

Avg Volume11K

Open$0.00

Beta-1.41

Overview

Molecular Pharmacology (USA), Ltd. (MLPH) Revenue

Annual & quarterly revenue history · segment & region breakdown

MLPH · revenue · updated Jun 9, 2026

Core revenue metrics

Trailing 12 months

Molecular Pharmacology (USA), Ltd. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY2024 $0.00B

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

1 employees

FY2024

$0.00B

FY2023

$0.00B

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · Molecular Pharmacology (USA), Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

2024 – 2002 · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth
2024-12-31	$0.00B	+$0.00B	—
2023-12-31	$0.00B	+$0.00B	—
2022-12-31	$0.00B	+$0.00B	—
2014-06-30	$0.00B	+$0.00B	—
2013-06-30	$0.00B	+$0.00B	—
2012-06-30	$0.00B	+$0.00B	—
2011-06-30	$0.00B	+$0.00B	—
2010-06-30	$0.00B	+$0.00B	—
2009-06-30	$0.00B	+$0.00B	—
2008-06-30	$0.00B	+$0.00B	—

MLPH revenue by year · MLPH revenue history · MLPH annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Molecular Pharmacology (USA), Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Molecular Pharmacology (USA), Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Molecular Pharmacology (USA), Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

MLPH revenue · 4 questions

MLPH's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.

MLPH revenueMLPH annual revenuewhat is MLPH revenueMLPH TTM revenue

▸ Source: FMP · Molecular Pharmacology (USA), Ltd. SEC filings · GAAP · Molecular Pharmacology (USA), Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026